Related Experiment Video

Updated: Jun 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Resistant hypercholesteremia in clinical practice: new insight into the causes and methods of treatment]

A N Kuchmin, S A Chernov, A N Teslia

    Voenno-Meditsinskii Zhurnal
    |March 15, 2011
    PubMed

    Insights

    Resistant hypercholesterolemia may indicate tissue insensitivity to thyroid hormones. Adding low-dose levothyroxine to statins effectively lowers cholesterol, improving lipid metabolism and reducing cardiovascular disease risk.

    Area of Science:

    • Cardiovascular Medicine
    • Endocrinology
    • Metabolic Disorders

    Context:

    • Atherosclerosis is a primary cause of adult mortality, driven by cholesterol metabolism dysregulation.
    • Ischemic heart disease mortality reduction relies on effective lipid metabolism correction.
    • Resistant hypercholesterolemia poses a significant challenge in cardiovascular disease management.

    Purpose:

    • To investigate the causes and correction strategies for statin-resistant hypercholesterolemia.
    • To explore the role of thyroid hormone sensitivity in resistant hypercholesterolemia.
    • To evaluate the efficacy of combining levothyroxine with statins for cholesterol reduction.

    Summary:

    • Some patients with statin-resistant hypercholesterolemia exhibit hypothyroidism symptoms despite normal thyroid hormone levels, suggesting tissue resistance.
    • Supplementing statin therapy with low-dose levothyroxine (25-50 mcg daily) demonstrated additional cholesterol-lowering effects.
    • This combination therapy enabled patients to achieve target lipoprotein levels, crucial for managing atherosclerosis.

    Impact:

    • Low-dose levothyroxine combined with statins offers a highly effective and cost-efficient approach to managing resistant hypercholesterolemia.
    • Improved lipid management through this combined therapy can contribute to reduced mortality from cardiovascular diseases.
    • This strategy addresses a critical unmet need in treating patients with difficult-to-manage cholesterol levels.

    More Related Videos

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Cholesterol: Significance and Regulation01:29

    Cholesterol: Significance and Regulation

    Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
    Considering cholesterol and...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Lipids: Dietary Sources and Requirements01:18

    Lipids: Dietary Sources and Requirements

    Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...